Biopharmaceutical company that produces Narcan, a naloxone nasal spray for opioid overdose reversal.
3 AI-extracted insights from 3 sources — podcasts, YouTube channels, and X/Twitter accounts.
Based on 1 scored insight about Emergent BioSolutions Inc..
The 3 sources with the most insights about Emergent BioSolutions Inc. on Kazuha.
AI-generated insights from podcasts, YouTube videos, and X posts — ordered by most recent.
Increased government focus on harm reduction and public health infrastructure is driving sustained demand for overdose reversal agents like Naloxone.
Factual news: An insider sold shares worth $306,080, which can be a bearish signal.
The spread of highly potent nitazines is expected to drive significant and sustained demand for overdose reversal drugs like Narcan, potentially expanding the market to Europe.
Increased government focus on harm reduction and public health infrastructure is driving sustained demand for overdose reversal agents like Naloxone.
Factual news: An insider sold shares worth $306,080, which can be a bearish signal.
The spread of highly potent nitazines is expected to drive significant and sustained demand for overdose reversal drugs like Narcan, potentially expanding the market to Europe.
Other assets that creators frequently mention in the same content as Emergent BioSolutions Inc..
The most active sources covering Emergent BioSolutions Inc. (EBS) on Kazuha are @realmartinshkreli, The New York Times, The Wall Street Journal & Spotify Studios. Kazuha aggregates AI-extracted insights from podcasts, YouTube channels, and X/Twitter accounts.
Kazuha has indexed 3 AI-extracted insights about Emergent BioSolutions Inc. (EBS) from 3 different sources. New insights are added whenever a covered creator publishes a new podcast episode, video, or post.
Creators covering Emergent BioSolutions Inc. (EBS) most frequently also discuss PFE, IBKR, IONQ, SLI, EQT. See the "Discussed alongside" section above for full asset pages.